ReachRxResearch
Home
Research
Sign Up
Venetoclax Plus Hypomethylating Agent for 7‐ Versus 14‐ Versus 21‐ Versus 28‐Day Cycles in Newly‐Diagnosed Acute Myeloid Leukemia: ELN and Mayo Genetic Risk–Stratified Analysis in 540 Patients
Back to Research Hub
  1. Home
  2. Research Hub
  3. Venetoclax Plus Hypomethylating Agent fo…

Venetoclax Plus Hypomethylating Agent for 7‐ Versus 14‐ Versus 21‐ Versus 28‐Day Cycles in Newly‐Diagnosed Acute Myeloid Leukemia: ELN and Mayo Genetic Risk–Stratified Analysis in 540 Patients

American Journal of Hematology·September 17Open Access
HematologyLimited evidenceAcute Myeloid LeukemiaRetrospective Cohort StudyBCL-2 InhibitorHypomethylating AgentAdultVenclextaAzacitidineDecitabineVenetoclax

Summary

View source

What was studied

In 540 newly-diagnosed AML patients treated with venetoclax plus a hypomethylating agent at Mayo Clinic, this retrospective study compared outcomes across four venetoclax cycle-1 durations (7, 14, 21, and 28 days), stratified by ELN 2024 and Mayo genetic risk groups, over a median follow-up of 37.7 months.

Key findings

Transplant-censored median survival did not differ significantly across venetoclax durations (13.3, 11.9, 16.8, and 13.2 months for 7-, 14-, 21-, and 28-day, respectively; p=0.65); prognosis was driven by ELN risk (6.3 vs. 11.5 vs. 18.3 months for high, intermediate, low; p<0.01) and Mayo genetic risk (6.9 vs. 17.8 months vs. not reached; p<0.01). Among ELN high-risk patients, 14-day venetoclax was associated with inferior transplant-censored survival vs. 21- and 28-day schedules (p<0.01).

Study limitations

Retrospective single-center design with likely treatment selection bias — shorter venetoclax schedules had higher 30- and 60-day mortality (7-day: 9%/18%; 14-day: 7%/15% vs. 28-day: 2%/6%), suggesting sicker patients were assigned shorter durations. Allogeneic stem cell transplant rates were similar across groups (~15–20%), limiting power to detect transplant-driven survival differences.

Clinical implications

Venetoclax duration alone (7 to 28 days) does not appear to be the primary driver of survival in newly-diagnosed AML; clinicians should weight ELN 2024 and Mayo genetic risk more heavily when counseling patients, though prospective risk-adapted trials are needed before shortening venetoclax cycles below 28 days — especially in ELN high-risk disease.

Caveats

  • Single-center retrospective design at Mayo Clinic limits generalizability to other practice settings and patient populations
  • The study does not report rates of remission (CR/CRi) or MRD negativity by venetoclax duration, which are key intermediate endpoints in AML
  • Treatment selection bias is likely: patients assigned shorter venetoclax durations (7–14 days) had substantially higher early mortality rates, suggesting they were clinically frailer or had higher-risk disease at baseline, which could confound comparisons across duration groups

Related Questions

Explore related topics

What is the optimal venetoclax duration in AML with ELN high-risk genetics?Venetoclax plus azacitidine vs decitabine outcomes in newly diagnosed AML by genetic risk groupRisk-adapted venetoclax dosing strategies in acute myeloid leukemia clinical trials

Publication Details

Year
2026
Journal
American Journal of Hematology
Sample Size
n=540
Source
View article
Keep scrolling
More content below.
Up Next